150,000 Shares in Metsera Inc. $MTSR Acquired by Siren L.L.C.

Key Points

• Siren L.L.C. has acquired a new position in Metsera Inc. by purchasing 150,000 shares, valued at approximately $4.08 million.
• Major investors like Alphabet Inc. and Bank of New York Mellon have also recently bought shares in Metsera, reflecting growing interest in the company.
• Analysts have set a consensus target price of $59.00, with several firms issuing buy ratings and increasing their price objectives for Metsera's stock.

Siren L.L.C. purchased a new stake in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 150,000 shares of the company's stock, valued at approximately $4,083,000. Siren L.L.C. owned about 0.14% of Metsera at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of MTSR. Alphabet Inc. purchased a new position in Metsera in the first quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in Metsera in the first quarter valued at approximately $78,748,000. Jennison Associates LLC purchased a new position in Metsera in the first quarter valued at approximately $9,679,000. Charles Schwab Investment Management Inc. purchased a new position in Metsera in the first quarter valued at approximately $3,410,000. Finally, TD Asset Management Inc purchased a new position in Metsera in the first quarter valued at approximately $2,091,000.

Metsera Stock Down 0.0%

Shares of NASDAQ:MTSR traded down $0.01 during trading hours on Wednesday, hitting $36.20. 573,901 shares of the company's stock traded hands, compared to its average volume of 1,006,510. The business has a fifty day moving average price of $34.25 and a 200-day moving average price of $28.56. Metsera Inc. has a 1 year low of $12.30 and a 1 year high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Wall Street Analyst Weigh In

Several equities analysts recently commented on MTSR shares. Guggenheim upped their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Bank of America lifted their price objective on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Metsera in a research note on Wednesday. Wells Fargo & Company started coverage on shares of Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Metsera from a "sell" rating to a "hold" rating in a research note on Saturday. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $59.00.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.